Main

A well-balanced immune response is of fundamental importance for the fitness and survival of the organism. An overactive pro-inflammatory state invariably leads to immune dysregulation, including a diverse range of autoimmune and inflammatory diseases7,8. Understanding the mechanisms that tune the immune response may afford important insights into the function of the immune system, and provide novel strategies to combat disorders and diseases characterized by dysregulated immune states.

Much is known about innate9 and adaptive immunity10, with numerous cellular and humoral factors having essential roles in initiating, amplifying and terminating immune responses11,12,13. Several studies have shown that infection can activate neural circuits mediating physiologically conserved responses such as fever, malaise and changes in feeding behaviour14,15,16,17, and pioneering work by Tracey and collaborators have revealed the significance of electrical stimulation of the vagal nerve as a therapeutic strategy to attenuate inflammation18. However, how the brain, as the central ‘arbiter’ of body physiology, regulates immunity remains poorly understood, despite our knowledge of several potential pathways linking the brain to immune cells19,20,21,22,23.

Here we describe a body–brain neural circuit that informs the brain of an emerging inflammatory response. We identified vagal neurons that respond to pro-inflammatory versus anti-inflammatory immune mediators, and showed that they signal to a genetically defined population of neurons in the brainstem to modulate and shape the course on an inflammatory response. These results reveal the influence of the body–brain axis in controlling innate immunity and highlight the therapeutic potential of recruiting this axis to help rebalance immune function.

Neurons activated by innate immunity

The brain monitors nearly all aspects of body biology, including responses to infection14, internal-state changes24, sickness and inflammation15,16,25,26. The notion that the brain and immune systems interact with each other has long been proposed21,27. However, the identity of the circuit elements linking peripheral immunity with the brain have remained largely unknown. We reasoned that if we could identify neuronal populations in the brain that are activated by a peripheral immune insult, it would help to dissect the neural control of immunity.

We used lipopolysaccahride (LPS), a canonical immune stimulus derived from the outer membrane of Gram-negative bacteria to elicit innate immune responses28. We challenged separate cohorts of mice with intraperitoneal injection of LPS and vehicle control (saline), and then examined the evoked immune response by measuring cytokine changes28,29 in peripheral blood samples. As expected, a single dose of LPS is sufficient to trigger significant increases in the levels of pro-inflammatory and anti-inflammatory cytokines, with a time course peaking at about 2 h after LPS injection (Fig. 1a). Next, we scanned the brains of the animals for induction of the immediate early gene Fos as a proxy for neural activity30 (see Methods for details). Our results showed stimulus-evoked labelling in the area postrema and strong labelling in the caudal nucleus of the solitary tract (cNST)15 in the brainstem (Fig. 1b and Extended Data Fig. 1); minor labelling was observed in response to control saline injections. The area postrema is known to be activated by body malaise17, and hence it would be expected to exhibit some labelling. The cNST, on the other hand, is the primary target of the vagus nerve2,31 and functions as the major conduit in the body–brain axis.

Fig. 1: Immune responses activate the brain via the vagal–brain axis.
figure 1

a, Schematic illustrating LPS-induced cytokine measurements (left). Wild-type mice were injected with saline or LPS, and peripheral blood was sampled every 2 h. Also shown are levels of IL-6, IL-1β, TNF and IL-10 by ELISA. LPS is in red or green; saline is in black; n = 5 mice. Values are means ± s.e.m. b, Schematic of FOS induction by LPS stimulation (top). Mice received an intraperitoneal injection of saline or LPS. Two hours later, brains were immunostained for FOS expression. Strong bilateral FOS labelling is detected in neurons of the cNST (highlighted in yellow) in LPS-stimulated mice (bottom); n = 5 mice. Quantification of FOS-positive neurons; the equivalent area of the cNST (200 × 200 μm, Bregma −7.5 mm) was processed for each sample (right). Values are mean ± s.e.m; Mann–Whitney U-tests, P = 0.008. Scale bars, 200 μm. AP, area postrema; DMV, dorsal motor vagal complex. c, Fibre photometry of LPS-evoked activity in the cNST (left). A GCaMP6s AAV was targeted to the cNST of Vglut2-cre mice (see Extended Data Fig. 5e). Neural responses following LPS (dark blue traces, 0.5 mg kg−1, n = 6; light blue traces, 0.1 mg kg−1, n = 4) and control saline (black traces, n = 6) (middle). Traces display mean (solid) and s.e.m. (shaded). The orange traces depict responses after bilateral vagotomy (n = 6). The saline and LPS injections were done as successive stimulations in the same animals. Scale bar, ΔF/F. The red arrow indicates time of injections. Quantification of responses (right). AUC, area under the curve. Values are mean ± s.e.m.; Wilcoxon test (saline versus LPS), P = 0.03; Mann–Whitney U-test (LPS versus vagotomy), P = 0.004; Mann–Whitney U-test (saline versus vagotomy), P = 0.18. Note the severe loss of LPS-evoked responses (approximately 80%) following removal of the vagal communication pathway. Schematics were created using BioRender (https://biorender.com).

Importantly, injection of LPS in animals with a homozygous knockout for Myd88 (an essential component of the LPS receptor in immune cells32) did not activate cNST neurons (Extended Data Fig. 2), showing that LPS stimulates cNST labelling via its action on immune cells. Robust cNST labelling was also observed in response to various other immune insults (Extended Data Fig. 1c,d).

To directly monitor the activation of cNST neurons following the peripheral LPS challenge, we targeted cNST neurons with an adeno-associated virus (AAV) with a GCaMP6s construct33 (see Fig. 1 caption), so as to drive expression of the activity reporter in cNST neurons, and recorded responses in awake behaving animals using fibre photometry (Fig. 1c). Our results demonstrated cNST activation that tracks the emergence and the development of the innate immune response (compare Fig. 1c with Fig. 1a).

If peripheral inflammation is sensed and transmitted by the vagus nerve to the cNST, then blocking the transfer of vagal signals should abolish LPS-evoked neural activity in the cNST. Indeed, bilateral subdiaphragmatic transection of the vagus nerve5,34 eliminated cNST responses to LPS (Fig. 1c). These results substantiate the vagal–cNST immune axis and demonstrate that the LPS-evoked activity is not the result of LPS directly accessing cNST neurons.

cNST silencing transforms body immunity

We anticipated that if the LPS-activated neurons in the cNST function as an essential circuit modulating peripheral immune responses, then blocking their activation should significantly affect the inflammatory response.

We used the targeted recombination in active populations (TRAP) system35 to target Cre-recombinase to the LPS-activated neurons (Extended Data Fig. 1e,f) and a Cre-dependent genetic silencer to examine LPS-evoked responses in control and silenced animals. First, to monitor the fidelity of the TRAP strategy, we confirmed that the LPS-activated cNST neurons marked by the expression of FOS are the same as the neurons labelled by Cre-recombinase in the genetic TRAPing experiments. We genetically labelled the LPS-induced TRAPed neurons with a Cre-dependent tdTomato reporter, and then performed a second cycle of LPS stimulation followed by FOS antibody labelling. Our results confirmed that the majority (more than 80%) of the LPS-TRAPed neurons (that is, labelled with tdTomato in the cNST) were indeed co-labelled with the FOS antibodies in response to the second cycle of LPS stimulation (Fig. 2a).

Fig. 2: Removing brain regulation transforms the inflammatory response.
figure 2

a, Neurons marked by LPS-TRAPing (red, tdTomato) are the same as the FOS neurons labelled after a second cycle of LPS (green; see Methods). By comparing the number of neurons expressing tdTomato to the number of neurons labelled by FOS antibodies, we determined that more than 80% of LPS-TRAPed neurons were also positive for LPS–FOS (n = 4). Scale bar, 50 μm. 4-OHT, 4-hydroxytamoxifen. b, Inhibition of LPS-activated neurons in the cNST greatly increases the inflammatory response. AAVs carrying an mCherry construct, or the hM4Di inhibitory DREADD, were targeted to the cNST of LPS-TRAP2 mice for chemogenetic silencing. Control mCherry animals injected with LPS (grey bars) exhibit the expected induction of cytokines. By contrast, animals with silenced cNST neurons displayed increases in the levels of pro-inflammatory cytokines and a large reduction in the levels of an anti-inflammatory cytokine (IL-10; compare red or green and grey bars). Mice in all groups were given CNO 1 h before either the saline or the LPS injection; n = 6 for each group. Values are mean ± s.e.m.; Mann–Whitney U-tests: P = 0.24 (saline, IL-6), P = 0.97 (saline, IL-1β), P = 0.78 (saline, IL-10), P = 0.004 (LPS, IL-6), P = 0.004 (LPS, IL-1β) and P = 0.002 (LPS, IL-10). c, Chemogenetic activation of the cNST neurons during an immune response suppresses inflammation. The levels of anti-inflammatory (IL-10) and pro-inflammatory (IL-6 and IL-1β) cytokines in mice expressing excitatory DREADD (hM3Dq), or mCherry, in response to LPS are shown. All animals were given CNO 1 h before either the saline or the LPS injection (n = 6 for each group). Values are mean ± s.e.m.; Mann–Whitney U-tests: P = 0.17 (saline, IL-6), P = 0.93 (saline, IL-1β), P = 0.37 (saline, IL-10), P = 0.002 (LPS, IL-6), P = 0.002 (LPS, IL-1β) and P = 0.002 (LPS, IL-10). Schematics were created using BioRender (https://biorender.com).

Next, we bilaterally injected the cNST of LPS-TRAPed animals with an AAV carrying a Cre-dependent inhibitory DREADD36 (iDREADD; see Methods for details). Hence, the TRAPed LPS-activated neurons would turn-on Cre-recombinase and enable expression of the Cre-dependent iDREADD, thus allowing chemogenetic inhibition of those cells. The iDREADD-expressing animals were then challenged with LPS, and we monitored the resulting immune response (Fig. 2b, top panel). Chemogenetic inhibition of the cNST neurons resulted in a dramatic increase in the pro-inflammatory response and a concomitant decrease of the anti-inflammatory response (Fig. 2b, bottom panels); in essence, a run-away, out-of-control inflammatory response. Indeed, the levels of pro-inflammatory cytokines rise to over 300% compared with the levels observed in LPS-treated but not silenced animals (for example, IL-1β goes from 200 pg ml−1 to 800 pg ml−1; Fig. 2b), whereas the anti-inflammatory component exhibited a profound reduction (IL-10 levels were reduced from 750 pg ml−1 to approximately 250 pg ml−1; Fig. 2b). These results suggest that the cNST functions as a homeostatic neural control of peripheral immune responses.

cNST activation suppresses inflammation

Given that silencing LPS-activated neurons in the cNST leads to greatly intensified inflammation, we hypothesized that artificial activation of this circuit should produce the opposite effect, and thus suppress inflammation. We used the TRAP system to virally target an excitatory, rather than inhibitory, DREADD (hM3Dq)36 to the LPS-activated neurons, and tested the effect of activation of this circuit on the LPS-evoked inflammatory response. As predicted, chemogenetic activation of the LPS-TRAPed neurons inhibited the pro-inflammatory response while substantially increasing the anti-inflammatory response. As shown in Fig. 2c, the levels of pro-inflammatory cytokines were reduced by nearly 70% from the levels observed in the control LPS-evoked responses, whereas anti-inflammatory levels were up nearly tenfold. Together, these silencing and activation experiments demonstrate that modulating the activity of these brainstem neurons can bidirectionally regulate peripheral inflammation. Activating this circuit in the absence of an immune challenge has no effect on cytokine levels, validating its role in monitoring and regulating an immune response rather than initiating it (for example, no LPS control in Fig. 2c and Extended Data Fig. 3a,b).

cNST neurons suppressing inflammation

To identify the cNST neurons modulating inflammation, we performed single-cell RNA sequencing (scRNA-seq) on 4,008 cells from the cNST (Fig. 3a). We then carried out scRNA-seq on 288 individual neurons TRAPed with LPS (along with approximately 100 unlabelled neurons) and showed that the LPS-TRAPed neurons are primarily found in three related glutamatergic clusters (clusters 7, 10 and 12, with a small number in cluster 2) (Fig. 3b) and one GABAergic cluster (cluster 15) (Extended Data Fig. 3c,d).

Fig. 3: A genetically defined population of cNST neurons modulates body immunity.
figure 3

a, scRNA-seq cataloguing neuronal clusters in the cNST. A uniform manifold approximation and projection (UMAP) plot of transcriptomic data reveals 14 glutamatergic neuronal clusters (1–14, in colour) and 6 GABAergic clusters (15–20, in grey). b, scRNA-seq of individual LPS-TRAPed neurons from the cNST. The tdTomato-labelled LPS-TRAPed cells were isolated by fluorescence-activated cell sorting and individually sequenced. The UMAP of LPS-TRAPed neurons was then superimposed to the cNST map, showing the LPS-TRAPed neurons (highlighted in red). c, UMAP plot showing the normalized expression of the Dbh gene (left) and the strategy for hM3Dq DREADD activation of the DBH-expressing cNST neurons (right). d, Chemogenetic activation of DBH cNST neurons suppresses inflammation. The levels of anti-inflammatory (IL-10) and pro-inflammatory (IL-6, IL-1β and TNF) cytokines in mice expressing either excitatory hM3Dq or mCherry 2 h after LPS stimulation are shown. All mice were given CNO 1 h before the injection of saline or LPS. n = 4 animals for each group. Note the major decrease in the levels of pro-inflammatory cytokines and the large increase in the levels of anti-inflammatory IL-10. Values are mean ± s.e.m.; Mann–Whitney U-tests: P = 0.08 (saline, IL-6), P = 0.20 (saline, IL-1β), P = 0.23 (saline, TNF), P = 0.77 (saline, IL-10), P = 0.03 (LPS, IL-6), P = 0.03 (LPS, IL-1β), P = 0.03 (LPS, TNF) and P = 0.03 (LPS, IL-10). Schematics in panels b,c were created using BioRender (https://biorender.com).

We next tested whether chemogenetic activation of the excitatory (glutamatergic) or inhibitory (GABAergic) neurons could alter LPS-induced responses. We injected AAVs carrying a Cre-dependent excitatory DREADD into the cNST of either Vglut2-cre or Vgat-cre mice. Our results showed that activation of excitatory, but not inhibitory, neurons effectively suppressed LPS-induced inflammation and largely mirrored the results obtained following activation of the LPS-TRAPed neurons (Extended Data Fig. 4a); no effect was observed when activating GABAergic neurons (Extended Data Fig. 4b). Next, we screened clusters 7, 10 and 12 for common, selectively expressed genes and identified the dopamine β-hydroxylase (Dbh)37 gene as a candidate marker (Fig. 3c). In contrast to previous reports15, DBH-expressing neurons in the brainstem are almost exclusively located in the cNST (see Extended Data Fig. 5 for details) and are strongly activated in response to LPS (Extended Data Fig. 6). We obtained Dbh-cre mice38 and targeted their cNST with an AAV encoding a Cre-dependent excitatory DREADD36. As anticipated, activation of DBH-expressing neurons in the cNST markedly suppressed pro-inflammatory cytokines while greatly enhancing the anti-inflammatory IL-10 levels (Fig. 3c,d), demonstrating the ability of these cNST neurons to drive immune suppression. Next, we ablated the DBH+ neurons in the cNST and, as expected (Fig. 2), we observed dysregulation of the immune response (Extended Data Fig. 7).

Vagal responses to immune cytokines

How do cNST neurons monitor peripheral immune activity to instruct appropriate immune modulation? Given that information is being transferred via the vagal body–brain axis (Fig. 1c), we reasoned that specific vagal neurons may respond to cytokines released during LPS-induced inflammation and inform the brain of the emerging immune response.

We implemented an in vivo calcium imaging platform6 to record immune-evoked neural activity in the nodose (vagal) ganglia where the cell bodies of vagal sensory neurons reside, while animals were challenged with different cytokines. We targeted the calcium indicator GCaMP6s33 to all vagal sensory neurons using a Vglut2-cre driver, and used a one-photon functional imaging setup to record real-time vagal neuron responses6 to cytokine stimuli delivered intraperitoneally. As control, we also imaged responses to LPS and to intestinal delivery of sugar, a stimulus known to activate the nutrient-sensing, gut–brain axis, via a specific population of vagal neurons5,6. Our results showed that anti-inflammatory and pro-inflammatory cytokines activate two discrete non-overlapping populations of vagal sensory neurons, each accounting for a small fraction of all nodose ganglion neurons (Fig. 4a; see the legend). As anticipated, these do not overlap with the sugar-sensing vagal neurons8 (Fig. 4a, bottom panel). Importantly, LPS does not directly activate vagal neurons (Fig. 4b).

Fig. 4: Vagal neurons responding to anti-inflammatory and pro-inflammatory cytokines.
figure 4

a, Recording of calcium responses in vagal neurons expressing GCaMP6s while stimulating mice with cytokines intraperitoneally. The heatmaps depict z-score-normalized fluorescence traces from two non-overlapping populations of neurons: responders to pro-inflammatory (Pro) cytokines (top panels) and responders to anti-inflammatory (Anti) cytokines (middle panels). Each row represents the activity of a single cell over 5 min. Stimulus was given at 60 s (dashed line). n = 5 mice, TNF (3 mice), IL-1β (2 mice) and IL-10 (5 mice); 21 of 423 imaged neurons responded to pro-inflammatory stimuli (13 to TNF and 8 to IL-1β), and 11 of 423 responded to IL-10. As positive controls, we used intestinal stimulation with glucose (Glu; 10 s); this activates the gut–brain axis5,6, but stimulates different vagal neurons (lower panels). These imaging experiments used cytokine concentrations that were lower or comparable with that measured during LPS-induced inflammation (see Extended Data Fig. 10b). The overall percent of responding neurons is similar to what is observed for vagal neurons dedicated to other body–brain signalling pathways2,6. i.p., intraperitoneal. b, Vagal neurons are not directly activated by LPS, even when using high concentrations of LPS (0.5 mg kg−1; n = 5 mice; pro: TNF; anti: IL-10). c, We carried out a similar experiment by using a perfusion chamber rather than intraperitoneal injections of LPS (see Methods). Each row in the heatmaps represents the averaged activity of a single cell to two trials. The dashed lines denote stimulus time window (180 s). n = 7 for IL-1β, n = 12 for IL-6 and n = 19 for IL-10. See also Extended Data Fig. 8. Schematics in panels a,c were created using BioRender (https://biorender.com).

Because the delivery of cytokines via intraperitoneal injections limits the ability to examine responses across repeat trials in the same animal, we implemented an in vivo preparation that enables repeated perfusion of cytokines over time (see Methods for details). As the small intestines are a major substrate of vagal innervation39 and house a vast reservoir of immune cells40 capable of releasing cytokines in response to LPS stimulation, we anticipated that this would provide an effective strategy. As expected, our results demonstrated reproducible vagal responses to cytokine stimulation (Fig. 4c and Extended Data Fig. 8), thus substantiating the proposal that cytokines themselves function as an immune mediator in the body–brain axis, with the vagal neurons functioning as the conduit transmitting the inflammatory information to the cNST. Two direct predictions emerge from these results. First, injection of cytokines should activate the cNST DBH neurons (Extended Data Fig. 6c,d), and second, activating the selective vagal neurons should modulate the immune response, much like activating the cNST target neurons (see below).

Vagal activation by inflammatory signals

Because of the significance of suppressing an inflammatory state by modulating brain–body signals, we focused first on identifying vagal neurons mediating anti-inflammatory responses. Our strategy was to use the scRNA-seq cell atlas of the nodose ganglion41,42,43 to target excitatory DREADDs to different populations, and assess the effect of activation on LPS-induced immune responses. To ensure that only vagal neurons are activated in these experiments, we directly injected the AAV-DIO-hM3Dq (DREADD) virus bilaterally into the nodose ganglia of the various Cre-reporter mouse lines (Fig. 5 and Extended Data Fig. 9). Our results showed that activating the transient receptor potential ankyrin 1 (TRPA1)-expressing vagal neurons5 dramatically enhanced the anti-inflammatory response, and severely suppressed the levels of pro-inflammatory cytokines (Fig. 5a,b). Indeed, we observed a more than 80% decrease in the circulating levels of pro-inflammatory cytokines and a nearly sixfold increase in the levels of IL-10. We next explored whether this enhancement of the anti-inflammatory response depends on the reduction of the pro-inflammatory cytokines. We performed a ‘clamping-like’ experiment that artificially maintains pro-inflammatory cytokines at high levels and examined the anti-inflammatory response when activating the TRPA1 neurons. Our results demonstrated that, despite persistently high levels of pro-inflammatory cytokines, IL-10 was still dramatically enhanced in response to TRPA1 neuronal activation (Extended Data Fig. 10a).

Fig. 5: Vagal control of inflammation.
figure 5

a, Chemogenetic activation of TRPA1 vagal neurons. hM3Dq was targeted bilaterally to the nodose ganglion of Trpa1-cre mice5. Control animals received AAV-DIO-mCherry. b, Chemogenetic activation of TRPA1 vagal neurons suppresses inflammation. The levels of IL-6, IL-1β and IL-10 cytokines in mice expressing hM3Dq (n = 7 mice) and mCherry (n = 4 mice) are shown. Blood was collected 2 h after LPS, and all animals were given CNO 1 h before LPS injection. Values are mean ± s.e.m.; Mann–Whitney U-tests: P < 0.01 (IL-6), P < 0.01 (IL-1β) and P < 0.01 (IL-10). c, Heatmaps depict z-score-normalized fluorescence traces from IL-10-responding TRPA1 vagal neurons. Each row represents the activity of a single cell over 15 min. The experiment was carried out using intraperitoneal injection or perfusion with similar results. n = 6 mice. Pro: IL-6, anti: IL-10. A total of 27 of 189 imaged TRPA1 neurons responded to IL-10. d, Chemogenetic activation of CALCA vagal neurons. AAV-DIO-hM3Dq was targeted bilaterally to the nodose ganglion of Calca-cre mice45. Controls received AAV-DIO-mCherry. e, Chemogenetic activation of CALCA vagal neurons reduces the levels of pro-inflammatory cytokines. The levels of anti-inflammatory (IL-10) and pro-inflammatory cytokines (IL-6 and IL-1β) in mice expressing hM3Dq (n = 11 mice) and mCherry (n = 9 mice) are shown. Blood samples were collected 2 h after LPS stimulation, and all animals were given CNO 1 h before injection of LPS. Values are mean ± s.e.m.; Mann–Whitney U-tests: P < 0.01 (IL-6), P = 0.001 (IL-1β) and P = 0.88 (IL-10). f, Heatmaps depict z-score-normalized fluorescence traces from CALCA vagal neurons in response to pro-inflammatory cytokines (IL-6 and IL-1β). The experiment was carried out using intraperitoneal injections; n = 6 mice. A total of 35 of 211 imaged CALCA neurons responded to the pro-inflammatory stimuli. Schematics in panels a,d were created using BioRender (https://biorender.com).

To define the response properties of the TRPA1-expressing vagal neurons, we targeted the expression of GCaMP6s33 and imaged their responses when the animals were challenged with anti-inflammatory or pro-inflammatory cytokines. Our experiments showed that IL-10, but not pro-inflammatory cytokines, activated the TRPA1-expressing vagal neurons (Fig. 5c and see also Extended Data Fig. 8e). Given these results, we hypothesized that removing the TRPA1-expressing vagal neurons from this circuit should prevent the transfer of anti-inflammatory signals to the brain. We genetically ablated TRPA1-expressing vagal neurons by targeting the diphteria toxin receptor44, and then challenged the animals with IL-10 or LPS. Indeed, our results demonstrated that the cNST was very poorly activated in response to injection of IL-10 (Extended Data Fig. 11a) and, more importantly, the anti-inflammatory response was severely truncated; IL-10 levels are only about 50% of what is observed in control animals after LPS stimulation, with no effect on the pro-inflammatory response (Extended Data Fig. 11b). These results reveal the TRPA1-expressing vagal neuron as a conduit for relaying anti-inflammatory signals via the body–brain axis to reinforce the anti-inflammatory state.

Next, we explored the vagal neurons responding to pro-inflammatory signals. Our experiments showed that calcitonin-related polypeptide-α (CALCA)-expressing neurons45 in the vagal ganglia responded selectively to pro-inflammatory stimuli (Fig. 5f) and their chemogenetic activation significantly altered the levels of circulating pro-inflammatory cytokines (Fig. 5d,e).

A vagal–cNST body–brain circuit

To demonstrate that the cNST DBH-expressing neurons receive direct input from the vagal ganglion neurons carrying the anti-inflammatory (expressing TRPA1) and pro-inflammatory (expressing CALCA) signals, we used a Cre-dependent monosynaptic retrograde viral reporter system. In essence, we infected the cNST of Dbh-cre animals with an AAV carrying a Cre-dependent glycoprotein coat and a surface receptor for a transsynaptic reporter. We then infected the DBH neurons expressing the viral receptor and G protein with a retrograde rabies reporter (RABV–dsRed)46,47, and examined whether they receive input from TRPA1 and CALCA vagal ganglion neurons. The results shown in Extended Data Fig. 12 demonstrate the transfer of the rabies reporter from the cNST to the vagal TRPA1 and CALCA neurons, confirming the monosynaptic connections between the immune-responding neurons in the vagal ganglia and DBH neurons in the cNST. Next, we targeted the excitatory DREADD to TRPA1 vagal neurons and showed that their stimulation indeed robustly activated DBH neurons in the cNST (Extended Data Fig. 12e).

Together, these results uncovered two lines of signalling from the vagal ganglia to the brain. One line (TRPA1) carries anti-inflammatory signals and acts on cNST neurons to enhance the anti-inflammatory response (for example, by positive feedback onto immune cells releasing anti-inflammatory cytokines) and helps to suppress the pro-inflammatory state. The other (CALCA neurons) responds to pro-inflammatory signals and helps to tune down the pro-inflammatory response (for example, by negative feedback onto immune cells releasing pro-inflammatory cytokines).

Activation of other vagal populations did not significantly impact the LPS-induced inflammatory responses (Extended Data Fig. 9), further illustrating the specificity of this body–brain circuit.

Restoring immune balance

We reasoned that exogenous activation of the body–brain anti-inflammatory regulatory circuit should protect animals from a runaway inflammatory response. Therefore, we injected control mice with lethal doses of LPS48 (that is, overwhelming the natural innate response) and performed the same injections in animals where this circuit had been chemogenetically activated by targeted expression of excitatory DREADD to the TRPA1 vagal neurons (Fig. 6a). In parallel, we also targeted the DBH-expressing neurons in the cNST. Remarkably, chemogenetic activation of either of these neuronal populations in this immunomodulatory circuit is sufficient to dramatically transform the survival of these animals to an otherwise lethal dose of LPS: approximately 90% of the mice were alive after the immune challenge (Fig. 6b).

Fig. 6: Vagal–brain restoration of immune balance.
figure 6

a, Activation of TRPA1 vagal neurons and DBH cNST neurons. AAV-DIO-hM3Dq was targeted bilaterally to the nodose ganglion of Trpa1-cre mice or the cNST of Dbh-cre mice. Control Cre-driver mice received AAV-DIO-mCherry. Mice were challenged with a lethal dose of LPS (see Methods), and the TRPA1 vagal or the DBH cNST neurons were activated by injection of CNO at 6-h intervals beginning 1 h before injection of LPS (four injections over 19 h). b, Activation of TRPA1 vagal (left) or DBH cNST (right) neurons rescues animals from LPS-induced sepsis. The graphs show survival curves. All groups received the same regime of CNO injections. mCherry (black lines; n = 9) and hM3Dq (green lines; n = 8 (vagal) and n = 9 (cNST)) are shown. Log-rank (Mantel–Cox) tests: P < 0.001 (vagal) and P < 0.001 (cNST). The red arrow denotes LPS injection. All mCherry control mice, in both groups, died within the first 4 days. c, DSS-induced ulcerative colitis. d, Activation of TRPA1 vagal neurons protects animals from DSS-induced colon damage. AAV-DIO-hM3Dq or mCherry was targeted bilaterally to the nodose ganglion of Trpa1-cre mice. All animals were provided with CNO in the drinking water (see Methods). Note the effect of DSS-induced inflammation on colon integrity (middle); the red arrows illustrate the loss of the distal colon in DSS-treated animals, but not in DSS-treated animals if this circuit was activated (right; n = 4; similar protection was observed in all animals). e, Bar graphs show levels of CXCL1 pro-inflammatory cytokine in control, DSS-treated and DSS-treated in combination with activation of TRPA1 vagal neurons. Values are mean ± s.e.m.; Mann–Whitney U-test: P = 0.03 (DSS, DSS + hM3Dq). f, Significant levels of occult stool blood is detected in the DSS-treated but not in the TRPA1 neuron-activated animals. Values are mean ± s.e.m.; Mann–Whitney U-test: P = 0.03. Schematics in panels a,c were created using BioRender (https://biorender.com).

Next, we used a mouse model of ulcerative colitis (dextran sodium sulfate (DSS)-induced intestinal inflammation)49 to examine whether activation of this immunomodulatory circuit can prevent the dramatic loss of colon integrity, increase of pro-inflammatory cytokine levels and high levels of faecal blood observed in this model of colon injury and inflammation. We exposed control mice and animals in which the TRPA1 vagal neurons had been chemogenetically activated by targeted expression of excitatory DREADD to DSS for 7 days (see Methods for details); this time is sufficient for the development of the severe pathologies triggered by DSS treatment50. DSS-treated control animals exhibited dramatic damage to the distal colon, showed significant occult stool blood and had a major increase in the levels of pro-inflammatory cytokines (Fig. 6c–f). By contrast, chemogenetic activation of the TRPA1 vagal neurons protected animals from all three pathological conditions (Fig. 6c–f, hM3Dq animals).

Finally, we hypothesized that activation of this body–brain immune regulatory circuit should influence responses to infection models. We reasoned that a persistent and artificially strong activation should lead to a severely reduced pro-inflammatory state and suppressed innate immune responses. To test this, we established a model of bacterial infection using intestinal Salmonella enterica subspecies enterica serovar Typhimurium51. As predicted (Extended Data Fig. 13a–c), strong, sustained activation of this circuit resulted in a dramatic increase in bacterial load in the DREADD-activated hosts, but not in control infected animals.

Discussion

A well-controlled innate immune response is the key to fighting an immune insult, while minimizing the risk of a dangerous out-of-control pro-inflammatory reaction. The brain has long been proposed to act as a master modulator of body biology, including organ function1,2, nutrient preference5,6 and metabolism3. The involvement of the vagus nerve in sickness (including fever, plasma corticosterone, hyperalgesia, and suppression of social and feeding behaviours)23 has long been appreciated. Over 20 years ago, pioneering studies by Tracey and colleagues18,52 have demonstrated that broad electrical stimulation of the whole vagal nerve bundle (that is, thousands of random different fibres, including afferent and efferent pathways) can protect animals from shock produced by high levels of TNF. That work helped to reveal the importance of the vagus nerve in modulating levels of TNF and inflammation52. More recently, it has been shown that chemical activation of vagal fibres53 also reduced the levels of TNF after LPS. However, the nature of the candidate body–brain circuit, the identity and role of the neuronal elements, and the logic of the system remained largely unknown.

Here we showed that cytokines themselves mediate the activation of the vagal–brain axis and characterized the key neuronal elements and the logic of the circuit. Most unexpectedly, this body–brain circuit modulates not only pro-inflammatory18,52 but also the anti-inflammatory response. Indeed, we identified a population of vagal neurons that respond to pro-inflammatory signals and a different population responding to anti-inflammatory signals that transfer inflammatory information from the body to neurons in the cNST.

This body–brain circuit monitors the development of an inflammatory response and ensures the homeostatic balance between the pro-inflammatory and anti-inflammatory state. Critically, removing this body–brain circuit during an innate immune challenge abolishes essential immune regulation, and an otherwise normal inflammatory response becomes unregulated and out of control. By contrast, exogenous activation of this circuit during an immune response can reduce the pro-inflammatory state while promoting anti-inflammatory responses. We propose that the cNST neurons function as a biological rheostat controlling the extent of the peripheral inflammatory response by exerting positive-feedback and negative-feedback modulation on immune cells. In this regard, we anticipate that the two vagal lines of information, from the periphery to the brain, will interact at the level of the cNST to coordinate the appropriate descending signals. It will be interesting to determine the nature of the cNST DBH-positive neurons targeted by each vagal line.

Dysregulation of the immune system, and an enhanced pro-inflammatory state, has been linked to a broad range of diseases, from diabetes54 to neurodegeneration55, attesting to the importance of a proper immune balance. Activation of the DBH-expressing neurons in the cNST during an immune response did not alter the levels of circulating corticosterone induced by LPS (Extended Data Fig. 13d,e). We suggest that pharmacologically targeting this circuit may provide exciting new strategies to modulate and manage immune disorders, including autoimmune diseases (for example, rheumatoid arthritis), cytokine storm, toxic shock and other hyperactive immune states, such as those promoted by new immunotherapies56. In the future, it would be of great interest to identify additional neuronal populations that may participate in this process and characterize the elements of this immunomodulatory body–brain circuit, including the nature of other ascending signals, descending signals and effectors.

Methods

Animals

All procedures were performed in accordance with the US National Institutes of Health (NIH) guidelines for the care and use of laboratory animals, and were approved by the Columbia University Institutional Animal Care and Use Committee. Both male and female mice at least 7 weeks of age were used in the study. C56BL/6J (JAX 000664); Myd88−/−57 (JAX 009088); TRAP2 (ref. 35) (JAX 030323); Dbh-cre38 (JAX 033951); Vip-IRES-cre58 (JAX 010908); Gpr65-IRES-cre59 (JAX 029282); Piezo2-cre60 (JAX 027719); Oxtr-IRES-cre61 (JAX 030543); Vglut2-IRES-cre62 (JAX 028863); Vgat-IRES-cre62 (JAX 016962); Ai9 (ref. 63) (JAX 007909); Ai96 (ref. 64) (JAX 028866); Ai162 (ref. 65) (JAX 031562); and Rosa-iDTR66 (JAX 007900) were obtained from the Jackson Laboratory. Trpa1-IRES-cre5 was generated in the Zuker laboratory. Calca-cre45 mice were a gift of R. Palmiter.

FOS stimulation and histology

Mice housed in their home cages were injected intraperitoneally with LPS (50 μg kg−1; 14011, Cell Signaling Technology), lipoteichoic acid (LTA; 1 mg kg−1; L2512, Sigma), flagellin (20 μg kg−1; SRP8029, Sigma Aldrich), profilin (20 μg kg−1; SRP8050, Sigma Aldrich), Zymosan (2.5 mg kg−1; Z4250, Sigma Aldrich), IL-10 (100 μg kg−1; 575804, BioLegend), a cocktail of IL-6 (100 μg kg−1; 575706, BioLegend), IL-1β (100 μg kg−1; 401-ML, R&D) and TNF (100 μg kg−1; 410-MT, R&D) or saline control (0.9% NaCl). Then, 2 h later, these mice were perfused transcardially with PBS followed by 4% paraformaldehyde. Brains were dissected, fixed in 4% paraformaldehyde overnight at 4 °C and then sliced coronally at 100 μm thickness. The brain sections were permeabilized and blocked with 10% normal donkey serum (S30, EMD Millipore) in PBS containing 0.3% Triton X-100. Sections were incubated with an anti-FOS primary antibody (226004, SYSY; guinea pig, diluted 1:5,000) at 4 °C overnight, followed by labelling with a secondary antibody (Alexa Fluor 647-conjugated donkey anti-guinea pig; 706605148, Jackson ImmunoResearch) at room temperature for 2 h. For RNA in situ hybridizations, fixed-frozen nodose ganglia or brains were sectioned at 16 μm thickness and processed for mRNA detection using the RNAscope Fluorescent Multiplex Kit (Advanced Cell Diagnostics) following the manufacturer’s instructions. The following RNAscope probes were used: Fos (316921-C2), Dbh (464621-C1), Trpa1 (400211-C3), Calca (578771-C2) and GFP (400281-C1). Images were acquired using an Olympus FluoView 1000 confocal microscope. Quantification of fluorescent signals was carried out by manually counting the number of positive neurons.

Stereotaxic surgery

All stereotaxic surgery procedures were carried out using aseptic technique. Mice were anaesthetized with a mixture of ketamine and xylazine (100/10 mg kg−1, intraperitoneally) and then positioned on a custom-built stereotaxic frame equipped with a closed-loop heating system to maintain their body temperature. The viral constructs were injected into the cNST through a small craniotomy. The injection coordinates (based on Paxinos stereotaxic coordinates) for virus delivery in the cNST were as follows: caudal 7.5 mm, lateral ±0.3 mm and ventral 3.7–4 mm, all relative to Bregma and the skull surface. In chemogenetic experiments, TRAP2, Dbh-cre, Vglut2-cre and Vgat-cre mice received bilateral injections of 200 nl of AAV9-Syn-DIO-hM3Dq (#44361-AAV9, Addgene) and 300 nl of AAV9-Syn-DIO-hM4Di (#44362-AAV9, Addgene) in the cNST. Equivalent volumes of AAV9-Syn-DIO-mCherry (#50459-AAV9, Addgene) were injected as controls. For fibre photometry experiments, Vglut2-cre mice were unilaterally injected with 100 nl of AAV9-Syn-Flex-GCaMP6s (#100845-AAV9, Addgene) in the cNST, and an optical fibre (400-μm core, 0.48 NA, Doric Lenses) was implanted 50–100 μm above the GCaMP virus injection site.

Fibre photometry and subdiaphragmatic vagotomy

Photometry experiments were conducted at least 14 days after the stereotaxic viral injection and fibre implantation (see the section on stereotaxic surgery for details). Before the experiments, mice were acclimated to the recording chamber for 1 h per day over 3 consecutive days. On the fourth and fifth days, mice were recorded for the bulk GCaMP responses to saline and LPS (0.5 mg kg−1), respectively, in a 5-h recording session. Saline and LPS were intraperitoneally injected 15 min after the onset of recording. Real-time population-level GCaMP fluorescence signals were detected, amplified and recorded using a RZ5P fibre photometry system with Synapse software (Tucker Davis Technologies), as previously described6,67. The collected data were downsampled, detrended and smoothed by a custom MATLAB code. The calcium transients were identified as previously described68,69,70, and the area under the curve (AUC) was calculated by integrating the fluorescence signal under identified calcium transients.

To assess the necessity of the vagus nerve in the cNST responses to LPS, a separate group of Vglut2-cre mice received bilateral subdiaphragmatic vagotomy as previously described5,34, following the injection of GCaMP virus and the implantation of the fibre in the cNST. Mice were anaesthetized with ketamine and xylazine (100/10 mg kg−1, intraperitoneally). The stomach and oesophagus were carefully exposed to avoid any damage to blood vessels or the liver. The dorsal and ventral branches of the vagus nerve along the subdiaphragmatic oesophagus were then exposed, and the right and left vagus nerves were transected. The abdominal muscle layer and skin were closed with sutures. Following the vagotomy procedure, the mice were given 2 weeks to recover before fibre photometry recordings. The expression of GCAMP and placement of optic fibres were histologically verified at the termination of the experiments.

Genetic access to LPS-activated neurons in the brain

The TRAP35 strategy was used in TRAP2 mice to gain genetic access to LPS-activated neurons in the cNST. The AAV-injected TRAP2 mice (2–3 weeks after viral injection) or TRAP2;Ai9 mice were first habituated to intraperitoneal injections by daily injection of 100 μl saline for 5 days. After habituation, LPS (50 μg kg–1) was given intraperitoneally, then 90 min later, 4-hydroxytamoxifen (4-OHT; 20 mg kg−1; H6278, Sigma) was administered. Mice were used for experiments a minimum of 4 weeks after this TRAP protocol; this extended waiting time is crucial to restore sensitivity to LPS after the initial LPS-induced TRAPing71.

Chemogenetic manipulation experiments and measurement of cytokines

Following bilateral injection with AAV9-Syn-DIO-hM3Dq in the cNST of Dbh-cre, Vglut2-cre or Vgat-cre mice, or in the nodose ganglion of Trpa1-cre, Calca-cre, Vip-cre, Gpr65-cre, Piezo2-cre and Oxtr-cre mice, the animals were allowed to recover for a minimum of 3 weeks before treatment with CNO (BML-NS105, Enzo Life Sciences). When using TRAP2 animals, at least 4 weeks elapsed between TRAPing and CNO treatment. Two doses (2 mg kg−1 and 1 mg kg−1) of CNO were given intraperitoneally at 12 h and 1 h before saline or LPS stimulation. Two hours after the intraperitoneal injection of saline or LPS (0.1 mg kg−1), blood samples were collected from either the submandibular or the tail vein. Cytokines in the blood were measured using commercially available ELISA kits (R&D), following the manufacturer’s instructions. Saline and LPS experiments were conducted on the same cohort of mice but at least 7 days apart.

To examine LPS-induced cytokine responses over time, wild-type (C56BL/6J) mice were injected intraperitoneally with saline or LPS, and peripheral blood samples were collected at 0, 2, 4 and 6 h post-stimulation.

To measure circulating cytokine levels following administration of exogenous cytokines, mice were injected intraperitoneally with IL-6 (100 μg kg−1), TNF (100 μg kg−1) or IL-10 (100 μg kg−1), and peripheral blood samples were harvested at 10 min and 2 h post-injection.

To ‘clamp’ pro-inflammatory cytokine levels, a cocktail of IL-6 (300 μg kg−1), IL-1β (15 μg kg−1) and TNF (30 μg kg−1) was injected with LPS.

Saporin ablation of DBH cNST neurons

Previous studies have shown that saporin-mediated targeted ablation is a highly effective method to kill DBH-expressing neurons72,73. We bilaterally injected the cNST of mice with an anti-DBH–saporin conjugate (20 ng per side; IT-03, Advaced Targeting Systems), and after 2–3 weeks recovery, animals were stimulated with LPS (0.1 mg kg−1) intraperitoneally. One hour following the LPS injections, blood samples were collected for measuring cytokine levels in the control and anti-DBH–saporin-treated animals.

scRNA-seq of cNST and LPS-TRAPed cells

To perform scRNA-seq74,75 on the entire cNST, we isolated single cells from the cNST as previously described76 with the following modifications. In brief, mice were anaesthetized with isoflurane and transcardially perfused with ice-cold carbogenated (95% O2 and 5% CO2) NMDG-HEPES-ACSF (93 mM NMDG, 2.5 mM KCl, 1.2 mM NaH2PO4, 30 mM NaHCO3, 20 mM HEPES, 25 mM glucose, 10 mM MgSO4, 1 mM CaCl2, 1 mM kynurenic-acid Na salt, 5 mM Na-ascorbate, 2 mM thiourea and 3 mM Na-pyruvate, pH 7.4). The brainstems were rapidly extracted and sliced into 300-μm sections containing the cNST using a vibratome (VT-1000S, Leica) in ice-cold NMDG-HEPES-ACSF solution with continuous carbogenation. The cNSTs were dissected, pooled (from five animals) and digested in Trehalose-HEPES-ACSF (92 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 30 mM NaHCO3, 20 mM HEPES, 25 mM glucose, 2 mM MgSO4, 2 mM CaCl2, 1 mM kynurenic-acid Na salt and 2.5 wt/vol trehalose, pH 7.4) containing papain (20 U ml−1; LK003150, Worthington) and DNase I (25 U ml−1) at 35 °C for approximately 1 h. Using Pasteur pipettes with progressively narrowing tip diametres, the tissue was triturated in DNase I-containing (25 U ml−1) Trehalose-HEPES-ACSF solution to form single-cell suspension. The dissociated cells were passed through a 40-μm filter and resuspended in resuspension-ACSF (117 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 30 mM NaHCO3, 20 mM HEPES, 25 mM glucose, 1 mM MgSO4, 2 mM CaCl2, 1 mM kynurenic-acid Na salt and 0.05% BSA, pH 7.4). The resulting cell suspension was processed by the Columbia Genome Core to encapsulate and barcode individual cells using the 10X Genomics Chromium system.

For sequencing LPS-TRAPed cells, we used TRAP2;Ai9 mice that were TRAP-labelled with tdTomato in response to LPS. Cells from the cNST were isolated as described above. The cell suspension was stained with DRAQ5 (62254, Thermo Scientific) and Calcein Violet (C34858, Thermo Scientific) to label viable cells, before FACS. A total of 288 tdTomato-positive LPS-TRAPped cells and 96 tdTomato-negative cells were sorted into 96-well plates pre-loaded with cell lysis buffer containing 0.1% Triton X-100, 0.5 U ml–1 SuperaseIN (AM2694, Ambion), 1 mM dNTP and 1 μM capture primer (that is, barcoding). cDNA was synthesized using Maxima Reverse Transcriptase (EP0753, Thermo Scientific) according to the manufacturer’s instruction. cDNA from all the wells/cells was combined, followed by clean-up using Silane beads (37002D, Thermo Scientific). Pooled cDNA was amplified using Kapa HotStart Mix with SMART PCR primer (0.2 μM), and then purified using AMPureXP beads (A63880, Beckman Coulter Life Sciences). Of cDNA, 0.6 ng was used as input to prepare libraries using Nextera XT kit (FC-131-1024, Illumina). The resulting libraries were sequenced on an Illumina sequencer.

scRNA-seq data analysis

Illumina sequencing reads were mapped to the mouse genome using the CellRanger pipeline with the default parameters. Analysis of scRNA-seq data, including the generation of cell clusters and identification of neuronal cluster markers, was performed using a custom R code developed following Seurat online instructions and vignettes77,78. We removed genes that were expressed in fewer than ten cells in the cNST-seq dataset, and in fewer than three cells in the TRAP2-seq dataset. In addition, we removed cells with low-depth sequencing (fewer than 2,000 genes in the cNST-seq dataset). To integrate datasets from cNST-seq and TRAP2-seq, we used the standard scRNA-seq integration procedure as outlined by Seurat (https://satijalab.org/seurat/). In brief, we first normalized each dataset and then used the Seurat ‘FindVariableGenes’ routine to identify 2,000 variable genes from each sample. Then, a common set of variable features were determined by Seurat ‘SelectIntegrationFeatures’ to merge samples. Finally, the first 25 principal components were used for generating cell types utilizing Seurat ‘FindClusters’.

Nodose ganglion injection experiments

The injection of AAV to nodose ganglion was performed as previously described5. In brief, Cre-expressing mice (Trpa1-cre, Calca-cre, Vip-cre, Piezo2-cre, Gpr65-cre and Oxtr-cre) were anaesthetized with intraperitoneal administration of ketamine and xylazine (100/10 mg kg−1). The skin under the neck was shaved and an incision (approximately 1.5 cm) in the midline was made. The trachea and surrounding muscles were gently retracted to expose the nodose ganglia. A mixture of Fast Green (F7252, Sigma) and AAV carrying the Cre-dependent excitatory DREADD (AAV9-Syn-DIO-hM3Dq) or control (AAV9-Syn-DIO-mCherry) was injected to both left and right ganglia using a 30° beveled glass pipette (Clunbury Scientific). The injection volume per ganglion was 300 nl. For experiments ablating TRPA1 neurons, we crossed Tpra1-cre mice to Rosa-DTR mice66, and bilaterally injected vagal ganglia with control PBS alone or PBS containing 2 ng DTX (200 nl total volume; D0564, Sigma Aldrich)44. At the end of surgery, the skin incision was closed using 5-0 absorbable sutures (421A, CP Medical). Following the procedure, mice were allowed to recover for a minimum of 21 days before testing. The viral expression and ablation efficiency were histologically confirmed by examining the nodose ganglia extracted from all tested animals; mice with insufficient viral expression, mistargeting of viral injection or unsuccessful ablation were removed from data analysis.

Vagal calcium imaging

Calcium imaging of the nodose ganglion was conducted as previously described5,6. For imaging in response to intragastric delivery of glucose (or linoleic acid) and intraperitoneal injections of saline control and cytokines, a typical recording session consisted of: (1) saline; (2) one of the three pro-inflammatory cytokines (TNF, IL-1β or IL-6); (3) anti-inflammatory cytokine (IL-10); and (4) and (5) two trials with glucose (or linoleic acid). Each trial was 5 min. Cytokines were injected 1 min after the onset of the recording. Glucose (500 mM) and linoleic acid (10%) was delivered intragastrically as previously described5,6. For all experiments, we used 100 μg kg−1 of each cytokine. To deliver cytokines extraintestinally, we placed a segment of the intestine in a custom-made perfusion chamber while still keeping it connected to the remainder of the gastrointestinal tract (no carbogenation). Each recording session included six interleaved trials, with two trials for each stimulus. Trials were 15 min long, and consisted of a 180-s baseline (saline), a 180-s cytokine or control stimulus and a 9-min washout (saline) period. The flow rates were maintained at around 600 μl min−1 throughout the experiment to minimize mechanical responses that may occur during the transition between trials. Cytokines were dissolved in saline at the concentration of 1 μg ml−1. During the entire perfusion session, all of the solutions were maintained at 37 °C.

Calcium imaging data collection and analysis

Imaging data were acquired exactly as previously described5,6. Neuronal activity was analysed for significant stimulus-evoked responses as described in ref. 6. We first computed the baseline distribution of deviations from the median for each cell throughout the entire experiment using periods before the stimulus delivery. Subsequently, this baseline was utilized to derive a modified z-score by subtracting the median and dividing by the median absolute deviation. Trials with an average modified z-score above 1.6 for the 180 s (stimuli delivered via intraperitoneal) or 480 s (stimuli delivered via perfusion) following the initiation of stimulation were classified as responding trials (all responders had minimal peak amplitudes of 1% ΔF/F). z-Scores from responders were normalized across stimuli to generate heatmaps of normalized fluorescence traces (see also refs. 5,6).

Mapping vagal-to-cNST circuit

For monosynaptic retrograde tracing experiments, the cNST of Dbh-cre animals were first injected with a 1:1 mixture of AAV1-DIO-TVA-mCherry and AAV1-DIO-G(N2C)-mKate46,47,79 followed by a second injection of EnvA-pseudotyped G-deleted rabies virus carrying a GFP reporter (RABV-N2C(ΔG)-GFP-EnvA)46,47,79 3 weeks later. Seven to ten days after RABV infection, the animals were euthanized to identify and examine presynaptic neurons in the nodose ganglion by RNA in situ hybridization.

To determine whether DBH neurons are activated by stimulation of TRPA1 vagal neurons, AAVs carrying the Cre-dependent excitatory DREADD (AAV9-Syn-DIO-hM3Dq) were injected into the nodose ganglia of Trpa1-cre mice (see the section ‘Nodose ganglion injection experiments’). Following injection, the animals were allowed to recover for a minimum of 3 weeks before TRPA1 vagal neuron activation with CNO. CNO (5 mg kg−1) was injected intraperitoneally, and 1 h later, mice were euthanized to examine co-expression of Fos and Dbh in the cNST by in situ hybridization.

Modulation of survival in LPS-induced endotoxaemia through chemogenetic activation of the vagal–brainstem axis

After bilateral injection of AAV9-Syn-DIO-hM3Dq or AAV9-Syn-DIO-mCherry (control) in the cNST of Dbh-cre mice and in the nodose ganglion of Trpa1-cre mice, animals were allowed to recover for a minimum of 3 weeks before the injection of LPS. CNO (5 mg kg−1) was intraperitoneally administered 1 h before a lethal dose of LPS (12.5 mg kg−1)48. Following the LPS challenge, CNO (5 mg kg−1) was administered every 6 h for a total of three doses; survival was monitored every 6 h.

DSS-induced colitis and chemogenetic activation of TRPA1 vagal neurons

Trpa1-cre mice were injected bilaterally in the nodose ganglia with AAV9-Syn-DIO-hM3Dq or control AAV9-Syn-DIO-mCherry. Three weeks later, they were exposed to 3% DSS in the drinking water50 for 7 days. CNO (0.03 mg ml−1) was added to DSS solution of the experimental cohort to concomitantly activate TRPA1 neurons. To motivate mice to drink, 10 mM Acek was added to the drinking mix in both groups. Colon morphology was examined at the termination of the experiment; CXCL1 levels were measured using ELISA (R&D). Faecal occult blood was monitored using Hemoccult Dispensapak Plus (61130, Beckman Coulter) according to the manufacturer’s instructions.

S. enterica serovar Typhimurium infection and chemogenetic activation of TRPA1 vagal neurons

Trpa1-cre mice injected with AAV9-Syn-DIO-hM3Dq or AAV9-Syn-DIO-mCherry (control) in the nodose were allowed 3–4 weeks for virus reporter expression, and then infected with 1–2 × 107 colony-forming units of S. enterica serovar Typhimurium (14028, American Type Culture Collection) through oral gavage51. CNO (5 mg kg−1) was injected at 12-h intervals beginning 12 h before S. enterica serovar Typhimurium gavage, for a total of eight injections over 4 days. As a proxy for the health of the animal, we monitored body weight daily. At day 5 post-infection, the tissues (spleen and mesenteric lymph nodes) were collected from the infected mice, homogenized for serial dilutions in PBS and plated on LB agar51; colony-forming units were counted after overnight incubation of the plates at 37 °C.

Statistics

No statistical methods were used to predetermine sample size, and investigators were not blinded to group allocation. No method of randomization was used to determine how animals were allocated to experimental groups. Statistical methods used include Mann–Whitney U-test, Wilcoxon test, one-way analysis of variance and log-rank (Mantel–Cox) test, and are indicated for all figures. All of the statistical tests are two-tailed. Analyses were performed in MATLAB, R, Python and GraphPad Prism 8. Data are presented as mean ± s.e.m.

Inclusion and ethics

We support an all-inclusive, diverse and equitable conduct of research.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.